The technology protected under the patent relates to specific methods for enhancing antigen-specific T-helper cell stimulation using small synthetic peptides. Both prophylactic and immunotherapeutic vaccine peptides are currently under development at Antigen Express.
The importance of antigen-specific T-helper stimulation in controlling the immune response has been demonstrated in many areas of immunology ranging from protection against infectious diseases to oncology to autoimmunity. Consequently, specific means for controlling T-helper cell stimulation offers the possibility of a range of therapeutics. Generex said that Antigen Express has aggressively pursued development and intellectual property coverage of its technology platforms as well as product development.